Skip to main content

Table 1 Patient characteristics in each of the phase III clinical studies, OSKIRA-1, -2 and -3.

From: Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis

Study OSKIRA 1 OSKIRA 2 OSKIRA 3 p
N 206 197 71  
Gender, n (%) Females 173 (84%) 169 (86) 55 (78) > 0.1
Age 53.0 (12.0) 54.4 (12.5) 54.1 (12.7) > 0.1
BMI 28.0 (6.1) 28.0 (6.4) 29.7 (6.7) > 0.1
Ethnicity, n (%) African decent 4 (2) 13 (6.6) 6 (8.4) < 0.0001
ASIAN 1 (0.5) 20 (10.2) 0
Caucasian 108 (52.4) 150 (76.1) 37 (52.1)
Hispanic or Latino 93 (45.1) 12 (6.1) 28 (39.4)
Other 0 2 (1.0%) 0
Disease duration, years (SD) 9.1 (7.9) 7.5 (8.6) 10.2 (7.8) < 0.0001
Disease activity score, mean (SD) 5.9 (0.8) 5.6 (0.9) 5.6 (0.4) > 0.1
Presence of erosions at baseline Yes 100 (49.8) 93 (47.2) 37 (52.1) > 0.1
Previous conventional DMARDs Yes 76 (36.9) 64 (32.5) 22 (31.0) > 0.1
Previous anti-TNFa treatment Yes 10 (4.9%) 36 (18.3%) 71 (100%) < 0.0001
Previous other biologics Yes 0 (0%) 0 (0%) 0 (0%) > 0.1
Escape at week 12 Yes 66 (32.0) 90 (45.7) 25 (35.2) 0.016
  1. Data is presented as mean (SD) or frequency (%) as appropriated. Significant difference between studies was estimated by either χ2 or Kruskal-Wallis test (alpha = 0.05)